

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060427 A2

(51) International Patent Classification⁷: **A61K 31/135**,
A61P 15/00, 25/00

(21) International Application Number: **PCT/US02/02038**

(22) International Filing Date: **23 January 2002 (23.01.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
09/770,393 29 January 2001 (29.01.2001) **US**

(71) Applicant: **SEPRACOR INC.** [US/US]; 111 Locke
Drive, Marlborough, MA 01752 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors: **YOUNG, James, W.**; 765 Talisman Court,
Palo Alto, CA 94303 (US). **JERUSSI, Thomas, P.**; 19 Gar-
vey Road, Framingham, MA 01701 (US).

Published:

— *without international search report and to be republished
upon receipt of that report*

(74) Agents: **LAWRENCE, III, Stanton, T.**, et al.; Pennie &
Edmonds LLP, 1155 Avenue of the Americas, New York,
NY 10036 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 02/060427 A2

(54) Title: METHODS OF USING AND COMPOSITIONS COMPRISING (+) SIBUTRAMINE OPTIONALLY IN COMBINA-
TION WITH OTHER PHARMACOLOGICALLY ACTIVE COMPOUNDS

(57) Abstract: This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; af-
fective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg
syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, dia-
betic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and
incontinence. The invention further encompasses pharmaceutical compositions and dosage forms which comprise optically pure (+)
sibutramine, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.